Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients
- PMID: 29126863
- DOI: 10.1016/j.soard.2017.09.005
Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients
Abstract
Background: Controlled attenuation parameter (CAP) is a novel, noninvasive technique for assessing hepatic steatosis. However, its role in morbidly obese individuals is unclear. The effect of bariatric surgery on inflammation and fibrosis needs to be explored.
Objectives: To assess the utility of CAP for assessment of hepatic steatosis in morbidly obese individuals and evaluate the effect of bariatric surgery on hepatic steatosis and fibrosis.
Setting: A tertiary care academic hospital.
Methods: Baseline details of anthropometric data, laboratory parameters, FibroScan (XL probe), and liver biopsy were collected. Follow-up liver biopsy was done at 1 year.
Results: Of the 124 patients screened, 76 patients were included; mean body mass index was 45.2 ± 7.1 kg/m2. FibroScan success rate was 87.9%. The median liver stiffness measurement (LSM) and CAP were 7.0 (5.0-9.5) kPa and 326.5 (301-360.5) dB/m, respectively. On liver histopathology, severe steatosis and nonalcoholic steatohepatitis were present in 5.3% and 15.8%; significant fibrosis (≥stage 2) and cirrhosis in 39.5% and 2.6%, respectively. Area under receiver operator characteristic curve of LSM for prediction of significant fibrosis (F2-4 versus F0-1) and advanced fibrosis (F3-4 versus F0-2) was .65 (95% confidence interval [CI]: .52-.77) and .83 (95% CI: .72-.94), respectively. The area under receiver operator characteristic curve of CAP for differentiating moderate hepatic steatosis (S2-3 versus S0-1) and severe hepatic steatosis (S3 versus S0-2) was .74 (95% CI: .62-.86) and .82 (95% CI: .73-.91), respectively. At 1-year follow-up, 32 patients underwent liver biopsy. In these patients, there was significant improvement in hepatic steatosis (P = .001), lobular inflammation (P = .033), ballooning (P<.001), and fibrosis (P = .003). Nonalcoholic steatohepatitis was resolved in 3 of 4 (75%) patients. LSM and CAP significantly declined.
Conclusions: LSM and CAP are feasible and accurate at diagnosing advanced fibrosis and severe hepatic steatosis in morbidly obese individuals. Bariatric surgery is associated with significant improvement in LSM, CAP, steatohepatitis, and fibrosis.
Keywords: Bariatric surgery; FibroScan; Morbid obesity; Nonalcoholic fatty liver disease (NAFLD); Transient elastography.
Copyright © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Comment on: utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.Surg Obes Relat Dis. 2018 Jan;14(1):91-92. doi: 10.1016/j.soard.2017.10.001. Epub 2017 Oct 6. Surg Obes Relat Dis. 2018. PMID: 29104002 No abstract available.
Similar articles
-
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25. Gastroenterology. 2019. PMID: 30689971
-
Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.Obes Surg. 2021 Feb;31(2):617-626. doi: 10.1007/s11695-020-04977-4. Epub 2020 Sep 17. Obes Surg. 2021. PMID: 33052552
-
Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity.Int J Obes (Lond). 2018 Nov;42(11):1900-1911. doi: 10.1038/s41366-018-0007-3. Epub 2018 Jan 30. Int J Obes (Lond). 2018. PMID: 29463916
-
Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis.Can J Gastroenterol Hepatol. 2021 Jan 20;2021:8859338. doi: 10.1155/2021/8859338. eCollection 2021. Can J Gastroenterol Hepatol. 2021. PMID: 33542909 Free PMC article.
-
When the liver gets stiff, the tough get moving.J Gastroenterol Hepatol. 2020 Jun;35(6):953-959. doi: 10.1111/jgh.14963. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31867782 Review.
Cited by
-
Current Controversies in Metabolic Surgery for Nonalcoholic Fatty Liver Disease.Obes Surg. 2019 Mar;29(3):1058-1067. doi: 10.1007/s11695-019-03705-x. Obes Surg. 2019. PMID: 30617917 Review.
-
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7. J Clin Exp Hepatol. 2023. PMID: 36950481 Free PMC article. Review.
-
Simple surrogate equations to predict controlled attenuation parameter values for screening non-alcoholic fatty liver disease in a Chinese population.Front Med (Lausanne). 2022 Jul 22;9:894895. doi: 10.3389/fmed.2022.894895. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35935792 Free PMC article.
-
Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects.World J Hepatol. 2019 Feb 27;11(2):138-149. doi: 10.4254/wjh.v11.i2.138. World J Hepatol. 2019. PMID: 30820265 Free PMC article. Review.
-
Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease.Theranostics. 2020 Mar 4;10(9):4277-4289. doi: 10.7150/thno.40249. eCollection 2020. Theranostics. 2020. PMID: 32226553 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous